Welcome to our dedicated page for RVL Pharmaceuticals plc news (Ticker: RVLP), a resource for investors and traders seeking the latest updates and insights on RVL Pharmaceuticals plc stock.
RVL Pharmaceuticals plc (RVLP) drives innovation in specialty ophthalmology and neurology treatments, most notably through its groundbreaking product UPNEEQ® – the first FDA-approved non-surgical solution for acquired blepharoptosis. This page serves as the definitive source for official company announcements, financial disclosures, and therapeutic developments.
Investors and industry professionals will find timely updates on regulatory milestones, clinical advancements, and corporate strategy. Our curated news collection includes earnings reports, partnership announcements, and progress updates on neurology-focused therapies for conditions like multiple sclerosis and Parkinson's disease.
Key areas of coverage include UPNEEQ® market adoption, Osmodex® technology applications, and strategic shareholder initiatives. All content is sourced directly from RVL Pharmaceuticals' verified communications to ensure accuracy and compliance.
Bookmark this page for streamlined access to RVLP's latest press releases and financial presentations. Check back regularly for updates on pharmaceutical innovations that combine clinical expertise with patient-centric solutions.
RVL Pharmaceuticals reported Q2 2022 UPNEEQ® net product sales of $8.4 million, a 42% increase from Q1. The company experienced a 16% rise in unique pharmacy-paid prescribers, reaching approximately 15,000. Despite total revenues dropping by $3.1 million year-over-year due to the absence of licensing revenue, UPNEEQ sales showed significant growth, up $6.9 million from the prior year. Net loss decreased to $(12.1 million) from $(22.0 million). Cash reserves at quarter-end were $27.4 million, supported by recent financing efforts.
RVL Pharmaceuticals has secured up to $68.9 million in financing through equity and non-dilutive debt, significantly bolstering its financial position. The deal includes $43.9 million in immediate funding from a private placement of shares and $20.0 million in second tranche senior secured notes, with an additional $25.0 million available contingent on revenue targets. This financing supports the commercialization of UPNEEQ, a treatment for low-lying eyelids, with positive feedback driving sales growth.
RVL Pharmaceuticals plc will announce its second quarter 2022 financial results on August 11, 2022, before U.S. markets open. This announcement will include a commercial update regarding UPNEEQ, the first FDA-approved non-surgical treatment for acquired blepharoptosis. CEO Brian Markison and other executives will host a conference call at 8:30 a.m. ET to discuss the results and answer questions. Investors can register for the call via a provided link, enhancing security and reducing wait times.
RVL Pharmaceuticals (Nasdaq: RVLP) announced expected second quarter 2022 net product sales of $8.4 million for UPNEEQ, a 42% increase from the previous quarter. Cumulative orders from 2,200 medical aesthetics practices reflect a 100% growth since Q1 2022. The company maintains its guidance for fourth quarter 2022 sales between $20 million and $25 million. The preliminary data, which is unverified, underscores the potential of UPNEEQ in the aesthetics market.
RVL Pharmaceuticals plc (NASDAQ: RVLP) held its Annual General Meeting on June 16, 2022, where independent shareholders approved a waiver under Rule 9 of the Irish Takeover Rules. The resolution, which saw 28,894,940 votes in favor and 1,340,770 against, allows for potential increases in shareholding by specific parties if the company issues up to 17 million new ordinary shares. With this, affected parties can raise their ownership percentage without triggering a mandatory offer to other shareholders. RVL focuses on the commercialization of UPNEEQ®.
RVL Pharmaceuticals plc (Nasdaq: RVLP) announced that CEO Brian Markison will present at two significant conferences. The H.C. Wainwright Global Investment Conference is scheduled for May 24, 2022, at 11:00 a.m. ET, in Miami Beach, FL, with a webcast available here. Another presentation will take place at the Jefferies Healthcare Conference on June 9, 2022, at 1:30 p.m. ET, in New York City, NY, which can be accessed here.
RVL Pharmaceuticals plc (Nasdaq: RVLP) reported a strong first quarter of 2022, achieving total revenues of $21.4 million, a significant increase from $0.9 million year-over-year. Notably, UPNEEQ net product sales reached $5.9 million, reflecting a 90% growth over the previous quarter. The company received $15.5 million from its Santen License Agreement. Despite a net loss of $(6.8) million, down from $(13.8) million in 2021, RVL reaffirmed its guidance for UPNEEQ sales in Q4 2022 at $20 to $25 million. The recent awards for UPNEEQ also highlight its market recognition.
RVL Pharmaceuticals plc (Nasdaq: RVLP) is set to release its first quarter 2022 financial results and provide a commercial update on May 12, 2022, before U.S. markets open. The conference call will feature CEO Brian Markison and other executives discussing key financial metrics and business strategies. RVL focuses on underserved patient populations in ocular and medical aesthetics, currently commercializing UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution) 0.1%. Investors can access the live webcast and replay on the company’s website.
FAQ
What is the market cap of RVL Pharmaceuticals plc (RVLP)?
